Second-generation Monoclonal Antibody Combo Focuses on the Immunocompromised
Tonix Pharmaceuticals Holding Corp. recently announced that it is obtaining an exclusive license from Columbia University in New York for the development of a portfolio of fully human (TNX-3600) and murine (TNX-4100) monoclonal antibodies (mAbs) for the treatment or prevention of SARS-CoV-2 infection.
The Company believes that murine mAbs, such as TNX-4100, have the potential to generate high-affinity antibodies that recognize different epitopes on the SARS-CoV-2 spike protein.
This is because mice have a different repertoire of antibodies than humans.
The technology for generating antibodies optimizes the selection of appropriate B cells by the timing of immunization, harvesting approach, and screening platform.
Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, commented in a press release on February 13, 2023, "Immunocompromised individuals, including organ transplant recipients, are at increased risk of severe COVID-19 and poor clinical outcomes."
"We believe there is a need for second-generation mAb treatments and prophylactics to protect this population."
Although five mAb products containing seven distinct mAbs received emergency use authorization from the U.S. Food and Drug Administration for either treatment or prevention of COVID-19, none have remained useful or available in the U.S. since January 26, 2023.
Other mAbs news is posted at Coronavirus Today.